

Meike Vogler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8450014/publications.pdf>

Version: 2024-02-01

38
papers

1,933
citations

377584

21
h-index

355658

38
g-index

39
all docs

39
docs citations

39
times ranked

3218
citing authors

#	ARTICLE	IF	CITATIONS
1	Unleashing the power of NK cells in anticancer immunotherapy. <i>Journal of Molecular Medicine</i> , 2022, 100, 337-349.	1.7	12
2	Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy. <i>Cell Death Discovery</i> , 2022, 8, 11.	2.0	7
3	It's time to die: BH3 mimetics in solid tumors. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 118987.	1.9	40
4	Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways. <i>Cell Death and Differentiation</i> , 2020, 27, 1878-1895.	5.0	8
5	DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition. <i>Biomolecules</i> , 2020, 10, 1081.	1.8	9
6	BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models. <i>Cell Death and Disease</i> , 2020, 11, 769.	2.7	15
7	MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. <i>Journal of Hematology and Oncology</i> , 2020, 13, 173.	6.9	91
8	A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. <i>British Journal of Cancer</i> , 2020, 122, 1544-1551.	2.9	19
9	Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-XL and MCL-1 leads to rapid induction of intrinsic apoptosis. <i>Cancer Letters</i> , 2020, 482, 19-32.	3.2	41
10	Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, 2150-2163.	1.7	30
11	Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis. <i>International Journal of Cancer</i> , 2020, 147, 1485-1498.	2.3	6
12	Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML. <i>Cell Death and Disease</i> , 2019, 10, 917.	2.7	27
13	Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. <i>Haematologica</i> , 2019, 104, 1016-1025.	1.7	14
14	Identification of Smac mimetics as novel substrates for p-glycoprotein. <i>Cancer Letters</i> , 2019, 440-441, 126-134.	3.2	8
15	Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations. <i>Biological Chemistry</i> , 2019, 400, 181-185.	1.2	8
16	KRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3K. <i>Cancer Research</i> , 2018, 78, 2000-2013.	0.4	15
17	Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. <i>Cancer Letters</i> , 2018, 428, 160-172.	3.2	38
18	BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis. <i>Cancer Letters</i> , 2018, 412, 131-142.	3.2	24

#	ARTICLE	IF	CITATIONS
19	BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis. <i>Oncogene</i> , 2018, 37, 5325-5339.	2.6	29
20	Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. <i>Cancers</i> , 2018, 10, 127.	1.7	26
21	S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. <i>Oncotarget</i> , 2018, 9, 20075-20088.	0.8	82
22	Targeting anti-apoptotic BCL-2 family proteins in haematological malignancies from pathogenesis to treatment. <i>British Journal of Haematology</i> , 2017, 178, 364-379.	1.2	74
23	Targeting BCL2-Proteins for the Treatment of Solid Tumours. <i>Advances in Medicine</i> , 2014, 2014, 1-14.	0.3	80
24	ABT-199 selectively inhibits BCL-2 but not BCL-2<L>1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. <i>British Journal of Haematology</i> , 2013, 163, 139-142.	1.2	93
25	Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls. <i>British Journal of Haematology</i> , 2013, 160, 725-733.	1.2	11
26	Response: BH3 mimetics modulate calcium homeostasis in platelets. <i>Blood</i> , 2012, 119, 1321-1322.	0.6	12
27	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. <i>Biochemical and Biophysical Research Communications</i> , 2011, 408, 344-349.	1.0	16
28	BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. <i>Blood</i> , 2011, 117, 7145-7154.	0.6	161
29	Diminished Sensitivity of Chronic Lymphocytic Leukemia Cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood. <i>Clinical Cancer Research</i> , 2010, 16, 4217-4225.	3.2	45
30	Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2010, 95, 1510-1518.	1.7	73
31	Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma. <i>Cancer Research</i> , 2009, 69, 2425-2434.	0.4	140
32	Response: Microenvironment-dependent resistance to ABT-737 in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 114, 2561-2562.	0.6	9
33	Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. <i>Blood</i> , 2009, 113, 1710-1722.	0.6	127
34	Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 4403-4413.	0.6	294
35	Targeting XIAP Bypasses Bcl-2-Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth <i>In vitro</i> and <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 7956-7965.	0.4	143
36	Small Molecule XIAP Inhibitors Cooperate with TRAIL to Trigger Apoptosis in Childhood Acute Leukemia Cells and Overcome Bcl-2-Mediated Resistance. <i>Blood</i> , 2008, 112, 857-857.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. <i>Oncogene</i> , 2005, 24, 7190-7202.	2.6	40
38	Sensitization for ^{137}Cs -Irradiation-Induced Apoptosis by Second Mitochondria-Derived Activator of Caspase. <i>Cancer Research</i> , 2005, 65, 10502-10513.	0.4	64